骨坏死治疗市场基于(主要区域、市场参与者、规模和份额)- 预测至 2030 年

  • Report Code : TIPRE00033413
  • Category : Pharmaceuticals
  • No. of Pages : 150
Buy Now

Osteonecrosis Treatment Market Size Report | Size, Share & Forecast 2030

Buy Now

【研究报告】骨坏死治疗市场规模预计将从2022年的6.3718亿美元增长到2030年的10.2192亿美元;预计 2022 年至 2030 年该市场的复合年增长率为 6.08%。
分析师的观点
骨坏死治疗市场分析解释了增长驱动因素,例如由于道路事故数量增加而导致的骨坏死病例增加、以及患者长期使用类固醇。此外,老年人口的激增和骨骼健康意识的增强也有利于骨坏死治疗市场的进步。然而,手术治疗的高成本和与治疗药物相关的风险阻碍了市场的增长。采用骨科生物制剂和再生疗法很可能成为 2022 年至 2030 年骨坏死治疗市场的未来趋势。
骨坏死,也称为股骨头缺血性坏死 (AVN),是一种由于骨坏死破坏而引起的疼痛性骨病。血液流向骨骼;随着时间的推移,病情会恶化并导致骨细胞死亡。骨坏死的危险因素包括骨折、髋关节脱臼、放射治疗和酗酒。
市场洞察
骨科损伤病例的增加和老年人口的增加推动骨坏死治疗市场的增长
根据克利夫兰诊所发布的统计数据.org 预计,到 2021 年,每年有 10,000-20,000 名美国人被诊断出患有 AVN,该病影响所有年龄和性别的个人。近 20% 经历过髋关节脱位的人会发生股骨头缺血性坏死。由于致命事故造成的骨和关节损伤数量不断增加,全球骨坏死病例不断增加。虽然股骨头坏死更常见于髋部,但它也会影响肱骨、膝盖和距骨的健康状况。根据 StatPearls 2023 年发表的一篇文章,美国 10% 的髋关节置换术是由 AVN 造成的,其中大多数是 30-65 岁的人群。髋部或膝盖移位可能会切断腿部的血液供应。结果,腿部组织可能无法获得足够的血液(一种称为缺血的情况)并且可能死亡(一种称为坏死的情况)。肘部或上臂骨折有时会阻碍前臂的血液流动,从而产生类似的并发症。当骨骼的血液供应中断时,一部分骨骼可能会死亡,导致骨坏死。根据 2022 年 1 月在 PubMed Central 上发表的一篇文章,开展了一项队列研究,纳入了 170,934 名严重创伤患者。研究得出结论,78.0%的外伤性髋关节脱位的重大创伤患者是在道路交通事故中受伤,特别是机动车事故(49.9%)。
老年人更容易发生骨坏死,因为他们更容易发生骨坏死变性和骨折。 PubMed 于 2020 年发表的一篇文章中进行了一项研究,旨在评估空心内固定对 73 名股骨颈骨折 (FNF) 患者的长期结局的有效性,同时确定影响结局的危险因素。研究结果显示,其中7人(即~10%)经历了股骨头坏死,其中4人接受了髋关节置换术。根据世界卫生组织 (WHO) 的数据,到 2030 年,全球每 6 人中就有 1 人年龄在 60 岁或以上,估计有 14 亿人年龄在 60 岁以上。因此,老年人口的迅速增长和对骨骼的认识不断增强健康青睐股骨头坏死治疗市场。

未来趋势
采用骨科生物制剂和再生疗法将成为骨坏死治疗市场的未来趋势
骨科再生是利用生物学优势来增强愈合、减轻疼痛、改善功能,为组织再生创造良好的环境,从而治愈骨科病症。介入性骨科生物制剂的功能基于骨科再生原理,正在彻底改变骨科医学领域。骨科生物制品源自患者的组织,例如骨髓或血液。它们由刺激肌肉骨骼损伤愈合的信号分子或细胞组成。
干细胞疗法、富血小板血浆疗法、生长因子和组织工程等再生疗法正在临床试验中进行研究和评估,以优化治疗结果。 PubMed Central 于 2023 年 1 月发表的一篇文章中,进行了一项研究,以评估使用生物制剂治疗一名 44 岁男性股骨头双侧 AVN 的情况。患者右股骨头接受骨髓抽吸浓缩物(BMAC),左股骨头接受成人自体活体培养成骨细胞,之后要求他进行数年随访。该研究得出的结论是,与未分化的 BMAC 混合物相比,使用分化的成骨细胞进行生物治疗是 AVN 股骨头的可行选择。
骨坏死治疗市场的主要参与者致力于创新治疗的研发以及产品的推出。 2021 年 2 月,Additive Orthopedics, LLC 的首款患者专用距骨垫片获得美国食品和药物管理局 (FDA) 批准,这也是世界上第一个人道主义用途植入物。同样,全球领先的医疗器械公司 Arthrex 目前正在提供用于治疗自发性膝关节骨坏死 (SONK) 的骨内生物成形 (IOBP) 技术。该技术包括对病变部位进行核心减压,然后直接应用浓缩骨髓抽吸物,该抽吸物是使用 Angel 浓缩富血小板血浆 (cPRP) 系统制备的。
报告细分和范围
“骨坏死”治疗市场”根据治疗类型、最终用户和地理位置进行细分。根据产品类型,市场分为药物和手术。就最终用户而言,市场分为医院、专科诊所、门诊手术中心等。骨坏死治疗市场根据地理位置分为北美(美国、加拿大和墨西哥)、欧洲(德国、法国、意大利、英国、俄罗斯和欧洲其他地区)、亚太地区(澳大利亚、中国、日本、印度、韩国和亚太其他地区)、中东和非洲(南非、沙特阿拉伯、阿联酋以及中东和非洲其他地区)以及南美洲和中美洲(巴西、阿根廷以及中南部和中美洲其他地区)美国)
基于治疗类型的见解
根据治疗类型,骨坏死治疗市场分为药物和手术。 2020-2030 年,药品细分市场占有率最高。然而,手术细分市场预计将以 7.63% 的最高复合年增长率增长。
基于最终用户的见解
就最终用户而言,骨坏死治疗市场分为医院、专科诊所、门诊手术中心和其他的。预计 2022 年至 2030 年,医院细分市场将创下市场最高复合年增长率。骨坏死治疗涉及复杂的手术,需要特殊的医疗护理,包括诊断、治疗和持续监测。医院在为骨坏死患者提供完整的医疗服务方面发挥着至关重要的作用。根据疾病的阶段和严重程度,他们为骨坏死提供多种治疗选择。这些治疗可能包括疼痛管理、物理治疗和生活方式改变等保守技术。此外,在严重的情况下,可能会进行保留关节手术或关节置换手术等手术治疗。
骨坏死治疗市场,按治疗类型 - 2022 年和 2030 年
区域分析
北美骨坏死治疗市场由于先进处理方案的高可用性和采用以及主要制造商集中在该地区等因素,预计在预测期内将以显着的速度增长。尤其是美国,骨坏死治疗的采用率很高。
该报告介绍了全球骨坏死治疗市场的重要参与者。其中包括诺华公司;梯瓦制药工业有限公司;齐默生物美特;辉瑞公司;斯赛克; Exactech公司;默克公司;雷迪博士实验室有限公司;维亚特里斯公司;和 Horizon Therapeutics plc。这些领先企业专注于扩大其市场份额和客户并使之多样化,从而挖掘骨坏死治疗市场中普遍存在的商机。
主要市场参与者的一些主要发展如下:
2022 年 5 月,Regrow Biosciences 获得了美国 FDA 和欧洲药品管理局 (EMA) 授予的 OSSGROW 孤儿药资格 (ODD)。该药物适用于患有骨坏死的患者。2021年4月,ECI Pharmaceuticals LLC与AiPing Pharmaceuticals, Inc.签署了独家经销协议。该协议使AiPing能够处理布洛芬400 mg、600 mg的销售、营销和分销、800 毫克片剂和叶酸 1 毫克片剂。2021 年 2 月,Additive Orthopedics 的全距骨置换植入物获得 FDA 批准,该植入物设计为距骨间隔器的人道主义用途装置,用于患者特定的股骨头坏死治疗在美国的距骨。
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What is osteonecrosis and what treatments are available in the market?

Osteonecrosis, also known as avascular necrosis (AVN), is a painful bone disease caused due to the disruption of blood flow to bones; the condition worsens with time and results in the death of bone cells. The risk factors for osteonecrosis include broken bones, dislocated hips, radiation therapy, and alcohol abuse. Treatments such as drugs including NSAIDs, blood thinners, cholesterol lowering drugs and surgical procedures such as total joint replacement/ total hip arthroplasty (THA), core decompression surgery, bone graft, osteotomy is available.

Which region is expected to witness significant demand for osteonecrosis treatment market in the coming years?

Global osteonecrosis treatment market is segmented by region into North America, Europe, Asia Pacific, Middle East & Africa and South & Central America. The osteonecrosis treatment market in North America is expected to grow at a significant rate during the forecast period owing to factors such as the high availability and adoption of advanced treatment options, and the concentration of key manufacturers in the region. The US, in particular, records a high adoption rate of osteonecrosis treatments.

What are the driving factors for the osteonecrosis treatment market across the globe?

The rising cases of orthopedic injuries and increasing geriatric population drive osteonecrosis treatment market growth.

Who are the key players in the osteonecrosis treatment market?

The osteonecrosis treatment market majorly consists of the players such include Novartis AG; Teva Pharmaceutical Industries Ltd.; Zimmer Biomet; Pfizer Inc.; Stryker; Exactech, Inc.; Merck & Co. Inc.; Dr. Reddy’s Laboratories Ltd.; Viatris Inc; And Horizon Therapeutics Plc.

What is the market CAGR value of osteonecrosis treatment market during forecast period?

The CAGR value of the osteonecrosis treatment market during the forecasted period of 2020-2030 is 6.08%

Which type of treatment held the largest share in the osteonecrosis treatment market?

The drugs segment dominated the global osteonecrosis treatment market and held the largest market share of 75.45% in 2022.

The List of Companies - Osteonecrosis Treatment Market

  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Zimmer Biomet
  • Pfizer Inc.
  • Stryker
  • Exactech, Inc.
  • Merck & Co. Inc.
  • Dr. Reddy’s Laboratories Ltd.
  • Viatris Inc
  • Horizon Therapeutics plc.

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Trends and growth analysis reports related to Pharmaceuticals : READ MORE..